Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients

Abstract Background Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with EGFR mutations. However, some patients do not respond well, and some experience rapid progression...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaodong Chai, Hongxia Li, Moxuan Yang, Junyang Zeng, Genxiu Chen, Yongmeng Li, Wei Wang, Zichen Liu, Kun Li, Tongmei Zhang, Shuhao Wang, Nanying Che
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Journal of Translational Medicine
Subjects:
Lung cancer
EGFR
TKI
WSI
Therapy response
Prognosis
Online Access:https://doi.org/10.1186/s12967-025-06956-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06956-8

Similar Items